Modulating ILC activity through cytokine therapy or targeting immune checkpoints (e.g., PD-1, Lymphocyte activation gene 3 protein (LAG3), T cell immunoglobulin, and mucin domain-containing protein 3 (TIM-3)) offers potential pathways to shift the balance between pro-tumor and anti-tumor activities of ILCs in the TME [117] (Figure 2 and Figure 3). This evidence concerns the gene LAG3 and neoplasm.